Raleigh Capital Management Inc. Sells 3,014 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Raleigh Capital Management Inc. cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,183 shares of the biopharmaceutical company’s stock after selling 3,014 shares during the period. Gilead Sciences accounts for 1.1% of Raleigh Capital Management Inc.’s portfolio, making the stock its 13th largest holding. Raleigh Capital Management Inc.’s holdings in Gilead Sciences were worth $2,788,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth about $25,000. Valued Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares during the period. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences during the 4th quarter worth approximately $29,000. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences in the 2nd quarter valued at $33,000. Finally, Quarry LP bought a new position in Gilead Sciences during the 2nd quarter worth $43,000. 83.67% of the stock is owned by institutional investors.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares in the company, valued at $9,113,308.50. This represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock valued at $42,130,461 in the last quarter. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Mizuho upped their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. BMO Capital Markets lifted their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. UBS Group raised their price objective on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. The Goldman Sachs Group upped their target price on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Finally, Robert W. Baird raised their price target on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Price Performance

Shares of GILD opened at $93.04 on Thursday. The business has a 50-day moving average of $91.63 and a 200-day moving average of $84.63. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The company has a market capitalization of $115.95 billion, a price-to-earnings ratio of 1,033.78, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the previous year, the company earned $2.29 EPS. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.31%. Gilead Sciences’s payout ratio is 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.